AKT3 and lung carcinoma: Patients with lung cancer who exhibited higher levels of AKT3 showed poorer overall survival (OS) (Figure 2A).The clinical significance of overall survival (OS, Figure 2B), progression-free interval (PFI, Figure 2C), pathological staging (Figure 2D), and quality of life outcomes (Figure 2E) were assessed.